761 related articles for article (PubMed ID: 18338833)
21. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B
Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071
[TBL] [Abstract][Full Text] [Related]
23. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
[TBL] [Abstract][Full Text] [Related]
24. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
25. [Expression of TRAIL gene eukaryotic expression vector modulated by the human telomerase reverse transcriptase gene core promoter in ovarian cancer cell line SKOV3].
Li HM; Yu YC; Song TB; Xin XY; Zhang M; Wei XL; Xu JH
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1106-9. PubMed ID: 18062877
[TBL] [Abstract][Full Text] [Related]
26. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
[TBL] [Abstract][Full Text] [Related]
27. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
[TBL] [Abstract][Full Text] [Related]
28. [Security of dual cancer-specific targeting vector and its cytotoxic effect when harbored].
Wang J; Gu JF; Yang SY; Xiao T; Qi R; Sun LY; Liu XY
Ai Zheng; 2006 Apr; 25(4):385-92. PubMed ID: 16613667
[TBL] [Abstract][Full Text] [Related]
29. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo.
Song MS; Jeong JS; Ban G; Lee JH; Won YS; Cho KS; Kim IH; Lee SW
Cancer Gene Ther; 2009 Feb; 16(2):113-25. PubMed ID: 18758435
[TBL] [Abstract][Full Text] [Related]
30. Cancer-specific killing by the CD suicide gene using the human telomerase reverse transcriptase promoter.
Liu J; Zou WG; Lang MF; Luo J; Sun LY; Wang XN; Qian QJ; Liu XY
Int J Oncol; 2002 Sep; 21(3):661-6. PubMed ID: 12168115
[TBL] [Abstract][Full Text] [Related]
31. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
32. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
33. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
34. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
35. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.
Lin T; Huang X; Gu J; Zhang L; Roth JA; Xiong M; Curley SA; Yu Y; Hunt KK; Fang B
Oncogene; 2002 Nov; 21(52):8020-8. PubMed ID: 12439752
[TBL] [Abstract][Full Text] [Related]
36. [Expression of TRAIL(114-281) mediated by adeno-associated virus and its tumoricidal activity].
Ma H; Liu YX; Liu SL; Xu RA; Zheng DX
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1635-41. PubMed ID: 15569460
[TBL] [Abstract][Full Text] [Related]
37. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
38. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumor model.
Shieh GS; Shiau AL; Yo YT; Lin PR; Chang CC; Tzai TS; Wu CL
Cancer Res; 2006 Oct; 66(20):9957-66. PubMed ID: 17047058
[TBL] [Abstract][Full Text] [Related]
39. Liver-specific gene therapy of hepatocellular carcinoma by targeting human telomerase reverse transcriptase with pegylated immuno-lipopolyplexes.
Hu Y; Shen Y; Ji B; Yin S; Ren X; Chen T; Ma Y; Zhang Z; Zhang Y
Eur J Pharm Biopharm; 2011 Aug; 78(3):320-5. PubMed ID: 21220007
[TBL] [Abstract][Full Text] [Related]
40. [Relationship between human telomerase reverse transcriptase transcriptional level and telomerase activity in three ovarian cancer cell lines].
Song Y; Kong BH; Liu PS; Ma DX; Jiang S
Ai Zheng; 2003 May; 22(5):486-91. PubMed ID: 12753708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]